# Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma

> **NCT05584852** · — · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 240 (estimated)

## Conditions studied

- Skeletal Muscle Radiodensity
- Myosteatosis
- Scr/CysC Ratio
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **OTHER:** 

## Key facts

- **NCT ID:** NCT05584852
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584852, "Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05584852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*